Where Will MacroGenics Inc (MGNX) Stock Go Next After It Is Up 5.22% in a Week?

The market has been neutral on MacroGenics Inc (MGNX) stock recently. MGNX gets a Neutral score from InvestorsObserver Stock Sentiment Indicator.

MacroGenics Inc has a Neutral sentiment reading. Find out what this means for you and get the rest of the rankings on MGNX!

See Full MGNX Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With MGNX Stock Today?

MacroGenics Inc (MGNX) stock is up 0.95% while the S&P 500 is down -0.02% as of 11:27 AM on Friday, Nov 24. MGNX is up $0.07 from the previous closing price of $7.39 on volume of 49,964 shares. Over the past year the S&P 500 is higher by 13.13% while MGNX is up 20.91%. MGNX earned $0.80 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 9.4.

More About MacroGenics Inc

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them. Click Here to get the full Stock Report for MacroGenics Inc stock.